Los Angeles Principal Kirk Dillman provides his perspective on a recent settlement by Theranos, a biotech startup accused of making false statements and misrepresentation that led a San Francisco-based hedge fund to invest more than the $96 million in what was deemed as flawed technology. Click here to read more.
